Solutions

Sophia CDMO delivers practical, phase-appropriate solutions for biologics sponsors who need to move faster, reduce technical risk, and secure reliable supply. Our solutions are built around common program challenges—accelerating early development, strengthening CMC packages for regulators, improving manufacturability, and ensuring predictable GMP execution. Whether you need targeted support or an integrated end-to-end partnership, Sophia CDMO tailors scope, governance, and deliverables to your molecule and milestones.

Integrated End-to-End CDMO Partnership

For sponsors seeking a single accountable partner, Sophia CDMO provides integrated development, analytics, and manufacturing services aligned to a unified CMC strategy.

Best for:

• Early-stage companies building CMC infrastructure
• Sponsors needing speed with clear technical governance
• Programs that cannot tolerate handoff risk between vendors

What you receive:

• A single integrated plan spanning process, analytics, quality, and manufacturing
• Cross-functional execution with consistent documentation standards
• A clear control strategy narrative that supports regulatory filings
• Predictable milestone tracking and sponsor-ready deliverables

Typical outcomes:

• Faster progression from development into GMP clinical supply
• Reduced rework driven by consistent analytical and process alignment
• Higher confidence during scale transitions and tech transfers

Rapid IND/CTA-Enabling Readiness

Sophia CDMO helps sponsors generate the process understanding, analytical readiness, and documentation required to support first-in-human studies without unnecessary overbuild.

Best for:

• Programs on an aggressive clinical timeline
• Sponsors moving from research-grade materials to GMP execution
• Molecules requiring quick feasibility and early stability understanding

Solution components:

• Fit-for-purpose process development focused on manufacturability
• Phase-appropriate analytical methods for release and stability
• Initial formulation support aligned to early clinical use
• Development summaries and documentation inputs for IND/CTA

Typical outcomes:

• A scalable process foundation with defined risks and next steps
• A stability strategy that supports clinical supply planning
• Reduced timeline risk through clear decision gates and governance

Process Optimization and Yield Improvement

Sophia CDMO supports programs that require improved productivity, better recoveries, or enhanced batch-to-batch consistency.

Best for:

• Programs with low titer, high variability, or unstable performance
• Sponsors preparing to scale and needing more robust operations
• Molecules with challenging impurity or aggregation profiles

Solution components:

• Upstream optimization (media/feed strategy, parameter refinement, variability reduction)
• Downstream optimization (step yield improvement, impurity clearance strengthening)
• Scale-down model work to enable efficient experimentation
• Data-driven recommendations with practical implementation steps

Typical outcomes:

• Improved yield and throughput
• Stronger impurity clearance and more consistent product quality
• A more defensible operating strategy for later-phase execution

CMC Risk Reduction and Control Strategy Development

Sophia CDMO helps sponsors identify and mitigate the technical and regulatory risks that create late-stage delays, including unclear CQAs, weak analytical packages, and under-defined process controls.

Best for:

• Programs transitioning from Phase I into later development
• Sponsors planning major process changes, scale shifts, or site transfers
• Teams preparing for regulatory interactions and wanting stronger CMC clarity

Solution components:

• Structured CQA and risk assessment support
• Control strategy definition linked to process capability and analytics
• Phase-appropriate characterization planning support
• Comparability planning for anticipated changes

Typical outcomes:

• Better decision-making with clearer technical priorities
• Fewer surprises during scale-up, tech transfer, and validation readiness
• Stronger CMC narratives for regulatory filings

Tech Transfer, Site Transfer, and Scale-Up

Sophia CDMO provides a structured approach to tech transfer and scale-up designed to protect product quality and prevent manufacturing disruption.

Best for:

• Transfers from sponsor sites, academic labs, or other CDMOs
• Programs that must scale rapidly to meet clinical or market demand
• Sponsors consolidating vendors or moving toward commercial readiness

Solution components:

• Gap assessment across process, analytics, materials, and documentation
• Transfer plans with roles, deliverables, acceptance criteria, and timelines
• Bridging strategy and comparability planning as needed
• Engineering runs and GMP readiness reviews before clinical manufacturing

Typical outcomes:

• Faster, more predictable transfers with fewer execution surprises
• Reduced deviation risk through defined readiness gates
• Clear documentation continuity for CMC filings and audits

GMP Clinical Manufacturing and Reliable Supply Execution

Sophia CDMO supports GMP manufacturing with disciplined execution, strong quality oversight, and clear sponsor communication.

Best for:

• Sponsors needing clinical supply with predictable scheduling
• Programs that require high documentation standards and audit readiness
• Teams seeking a manufacturing partner with responsive governance

Solution components:

• GMP batch execution support aligned to sponsor oversight expectations
• Deviation, investigation, and CAPA management coordination
• Batch record and documentation package delivery designed for filing readiness
• Manufacturing summaries and trend reporting (as appropriate)

Typical outcomes:

• Reliable clinical supply manufacturing execution
• Higher confidence in batch documentation quality
• Improved transparency during manufacturing campaigns

Analytical Readiness, Method Development, and Method Transfer

Sophia CDMO supports analytical packages that enable faster development decisions and stronger regulatory submissions.

Best for:

• Programs lacking stability-indicating methods or robust release testing
• Sponsors preparing for tech transfer, comparability, or phase transition
• Molecules requiring deeper characterization to manage heterogeneity

Solution components:

• Fit-for-purpose method development and qualification planning
• Method transfer and verification support
• Stability program design and execution support
• Data packages suitable for CMC documentation

Typical outcomes:

• Reduced risk of late-stage method failures or rework
• Stronger comparability readiness
• Better alignment between process decisions and analytical evidence

Troubleshooting and Remediation

When programs encounter performance issues—low yields, unexpected impurities, stability failures, or manufacturing deviations—Sophia CDMO provides structured troubleshooting with clear root cause discipline.

Best for:

• Programs with recurring deviations or unresolved investigations
• Unexpected aggregation, potency shifts, or impurity excursions
• Scale-up challenges where lab performance doesn’t translate to manufacturing

Solution components:

• Rapid assessment of available data and process history
• Root cause hypothesis generation and test plan design
• Targeted experiments and analytical evaluations
• Corrective action recommendations with implementation support

Typical outcomes:

• Faster identification of true root cause drivers
• Practical fixes that can be implemented in GMP operations
• Reduced recurrence risk through improved controls and monitoring

Flexible Engagement Models

Sophia CDMO offers engagement structures designed to match sponsor needs and internal capabilities:

• Full program partnership: integrated development through manufacturing
• Module support: upstream only, downstream only, analytics only, or manufacturing only
• Hybrid model: Sophia CDMO leads critical-path activities while sponsor retains specific functions
• Milestone-based scopes: defined deliverables aligned to funding or clinical gates

Each model includes defined governance, timelines, and deliverable standards.

How Sophia CDMO Works With You

Structured Program Start

Most engagements begin with:

• A technical review (molecule, stage, goals, risks)
• A phase-appropriate workplan and timeline
• Defined deliverables and acceptance criteria
• Governance cadence and escalation pathways

Transparent Communication

We provide:

• Routine program updates with clear action logs
• Risk and change visibility (scope, technical impact, timeline implications)
• Sponsor-ready documentation packages designed for audit and filing needs

Focus on Practical Outcomes

Sophia CDMO emphasizes:

• Work that unlocks the critical path
• Data that supports decisions, not just testing
• Documentation quality that reduces downstream regulatory friction

Common Sponsor Needs We Support

Sponsors typically engage Sophia CDMO to achieve one or more of the following:

• Accelerate entry into clinic with a fit-for-purpose CMC package
• Improve yield and consistency to meet supply demand
• Resolve impurity, stability, or potency issues
• Transfer processes reliably across scale or site
• Strengthen CMC documentation for investor, partner, or regulator scrutiny
• Secure predictable GMP manufacturing with strong quality oversight